Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Three measures for simultaneously evaluating benefits and risks using categorical data from clinical trials.

C Chuang-Stein1, N R Mohberg, M S Sinkula

  • 1Upjohn Company, Kalamazoo, MI 49001.

Statistics in Medicine
|September 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selection bias for treatments with positive Phase 2 results.

Pharmaceutical statistics·2020
Same author

Recent Developments in the Prevention and Treatment of Missing Data.

Therapeutic innovation & regulatory science·2018
Same author

Discounting phase 2 results when planning phase 3 clinical trials.

Pharmaceutical statistics·2012
Same author

Biopharmaceutical statistics in a pharmaceutical regulated environment: past, present, and future.

Journal of biopharmaceutical statistics·2002
Same author

Metaanalysis of trials of tirilazad mesylate in aneurysmal SAH.

Acta neurochirurgica. Supplement·2001
Same author

Laboratory data in clinical trials: a statistician's perspective.

Controlled clinical trials·1998

This study introduces three novel measures to simultaneously assess treatment benefits and risks, aiding personalized treatment decisions. These methods incorporate patient preferences for evaluating clinical trial outcomes effectively.

Area of Science:

  • Clinical Trials
  • Medical Decision Making
  • Health Outcomes Research

Background:

  • Randomized clinical trials (RCTs) are crucial for comparing treatment efficacy and side effects.
  • Individual treatment decisions require evaluating benefits against risks based on personal preferences.
  • Existing methods may not adequately capture the nuanced balance of benefits and risks for individual patients.

Purpose of the Study:

  • To propose three novel quantitative measures for simultaneously assessing treatment benefits and risks.
  • To develop methods that incorporate individual patient preferences into benefit-risk evaluations.
  • To provide tools for facilitating informed treatment decisions based on clinical trial data.

Main Methods:

  • Development of three distinct measures for benefit-risk assessment.

Related Experiment Videos

  • Incorporation of individual outcome weights reflecting patient preferences.
  • Application of proposed measures to data from a phase III antihypertensive clinical trial.
  • Two measures are based on benefit/risk ratios; the third generalizes Hilden's measure.

    • Main Results:

    • The proposed measures provide a framework for quantifying and comparing treatments based on individual benefit-risk evaluations.
    • Demonstration of the utility of the measures using real-world clinical trial data.
    • The methods allow for a more personalized approach to treatment selection.

    Conclusions:

    • The developed measures offer a valuable approach to synthesizing complex clinical trial data for individual decision-making.
    • These tools can enhance shared decision-making between clinicians and patients regarding treatment options.
    • Further application of these measures can improve the personalized use of therapeutic interventions.